Monitor enrollment updates and interim data readouts from RECLAIM-LN. The RMAT designation and FDA CMC pilot program support accelerated pathway, but no efficacy data expected for 12-18 months. Stock movement likely driven by enrollment pace and any early safety signals.
Drug in focus
FATE drug pipeline →FT819
● Neutral Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- FT819 is in Phase 2 testing (RECLAIM-LN, a potentially registrational trial) that began enrolling in August 2026. If successful, an FDA submission could be several years away, likely in 2028-2029 at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst for FT819 is the Phase 2 RECLAIM-LN interim data expected in H2 2027. Positive data would validate the registrational trial and could drive significant upside for this single-asset-focused biotech. Negative or mixed data would be bearish. The stock trades at $1.26 with a 52-week range of $0.95-3.23. The newly effective $100M ATM facility signals potential near-term dilution risk.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 14 $2.57entry
- T+1 · 3mo ago +1.95%α +2.42% · $2.62
- T+5 · 3mo ago −9.34%α −7.97% · $2.33
- T+20 · 2mo ago −8.95%α −6.96% · $2.34
- T+60 · 8d ago −24.51%α −21.47% · $1.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for lupus nephritis. The trial targets ~53 patients with enrollment expected to complete by 1H2028, supported by RMAT designation and FDA CMC pilot program. This is a positive clinical milestone but no efficacy data is expected for 12-18 months.
Key Facts
- First patient dosed in Phase 2 RECLAIM-LN trial (FT819) for refractory lupus nephritis
- Trial expected to enroll ~53 patients; enrollment completion anticipated by 1H2028
- Primary endpoint: complete renal response at Week 26
- FT819 has RMAT designation and is in FDA CMC Development and Readiness Pilot program
- Patients receive single 900M-cell dose of off-the-shelf FT819 with bendamustine conditioning
Financial Impact
Clinical milestone with no immediate revenue impact; trial enrollment expected to complete by 1H2028. Cash runway into 2028 per prior Q2 filing.
Risk Factors
- Trial enrollment delays or slower-than-expected site activation
- Negative efficacy or safety data from Phase 2
- Dilution risk given cash burn and no revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345223 |
Track record
21 reports on FATE
4 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 Now $1.14 +10.94% settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 Now $1.14 −35.59% settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 Now $1.14 −37.87% ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 Now $1.14 +37.87% ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 Now $1.14 −38.38% ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 Now $1.14 −45.45% ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 Now $1.14 −44.12% ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers